> SELLAS Life Sciences announced that in a Phase II study of its WT1 cancer vaccine in malignant pleural mesothelioma patients, top-line data demonstrated clinical significant increases in overall survival and progression-free survival. Release
> Aridis Pharmaceuticals announced that it has received several National Institutes of Health grants, one of which is to develop technology to encase proteins into room temperature stable formulations for simpler vaccines storage. Release
> An attempt to repeal California's strict vaccination requirements for schoolchildren fell short of signatures. More